CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Mechanical circulatory support devices in advanced heart failure: 2020 and beyond Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.